SIX · ROP.SW
Roche Holding AG
CHF 403.40+CHF 1.70 (+0.42%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
Loading market information…
SIX · SFZN.SW · CHF
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Siegfried Holding AG’s quoted price sits in the lower half of its reported 52-week range, 29.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Siegfried Holding AG’s forward annual dividend is CHF 0.40 per share, paid annual. The forward yield is 0.56% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Siegfried Holding AG’s next earnings report is currently expected on Feb 19, 2027, with estimated earnings per share of CHF 2.51. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Siegfried Holding AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2023 | Apr 18, 2024 | CHF 1.32-28.65% vs estimate | CHF 664.44M-0.71% vs estimate |
|---|
| Q2 2023 | Aug 17, 2023 | CHF 1.30-4.41% vs estimate | CHF 607.05M+3.87% vs estimate |
|---|
| Q4 2022 | Feb 22, 2023 | CHF 2.18+30.54% vs estimate | CHF 642.78M-49.25% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 403.40+CHF 1.70 (+0.42%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
CHF 644.20+CHF 3.40 (+0.53%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
CHF 192.85+CHF 3.15 (+1.66%)
Galderma Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.54% below the high.
CHF 82.38-CHF 1.00 (-1.2%)
Sandoz Group AG’s quoted price sits in the upper half of its reported 52-week range, 3.78% below the high.
CHF 84.05-CHF 0.30 (-0.36%)
Bachem Holding AG’s quoted price sits in the upper half of its reported 52-week range, 2.27% below the high.
CHF 283.50+CHF 0.50 (+0.18%)
Dottikon ES Holding AG’s quoted price sits in the lower half of its reported 52-week range, 28.41% below the high.
CHF 42.00-CHF 1.40 (-3.23%)
PolyPeptide Group AG’s quoted price sits in the upper half of its reported 52-week range, 16.17% below the high.
CHF 17.05-CHF 0.35 (-2.01%)
Curatis Holding AG’s quoted price sits in the lower half of its reported 52-week range, 38.89% below the high.
